AstraZeneca Pharma India (BOM:506820) Cyclically Adjusted Revenue per Share: ₹524.50 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:506820 AstraZeneca Pharma India Ltd BOM:506820
85 GF Score
Price ₹7,410.50
GF Value ₹11,404.90
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AstraZeneca Pharma India Cyclically Adjusted Revenue per Share?

AstraZeneca Pharma India BOM:506820 -1.25% 85 Cyclically Adjusted Revenue per Share is ₹524.50 as of Jun. 2026. GuruFocus rates BOM:506820 with a GF Score™ of 85/100 and a GF Value™ of ₹11,404.90 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AstraZeneca Pharma India's adjusted revenue per share for the three months ended in Jun. 2026 was ₹273.083. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹524.50 for the trailing ten years ended in Jun. 2026.

During the past 12 months, AstraZeneca Pharma India's average Cyclically Adjusted Revenue Growth Rate was 17.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 13.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AstraZeneca Pharma India was 13.50% per year. The lowest was 7.40% per year. And the median was 9.70% per year.

As of today (2026-08-24), AstraZeneca Pharma India's current stock price is ₹7410.50. AstraZeneca Pharma India's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹524.50. AstraZeneca Pharma India's Cyclically Adjusted PS Ratio of today is 14.13.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AstraZeneca Pharma India was 24.88. The lowest was 8.17. And the median was 13.10.


AstraZeneca Pharma India  (BOM:506820) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AstraZeneca Pharma India's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7410.50/524.50
=14.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AstraZeneca Pharma India was 24.88. The lowest was 8.17. And the median was 13.10.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AstraZeneca Pharma India Cyclically Adjusted Revenue per Share Related Terms


AstraZeneca Pharma India Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for AstraZeneca Pharma India's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Pharma India Cyclically Adjusted Revenue per Share Chart

AstraZeneca Pharma India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 308.92 339.75 373.98 423.00 496.68

AstraZeneca Pharma India Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 442.26 463.44 481.57 496.68 524.50

BOM:506820 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Pharma India Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca Pharma India's Cyclically Adjusted PS Ratio falls into.


BOM:506820
85GF Score
AstraZeneca Pharma India Ltd BOM:506820
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Pharma India Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca Pharma India's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=273.083/167.3573*167.3573
=273.083

Current CPI (Jun. 2026) = 167.3573.

AstraZeneca Pharma India Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 55.094 105.961 87.017
201612 60.076 105.196 95.575
201703 46.229 105.196 73.546
201706 51.017 107.109 79.714
201709 65.680 109.021 100.824
201712 51.405 109.404 78.635
201803 60.238 109.786 91.826
201806 65.145 111.317 97.941
201809 64.498 115.142 93.747
201812 86.102 115.142 125.148
201903 67.538 118.202 95.624
201906 81.861 120.880 113.336
201909 83.450 123.175 113.383
201912 89.542 126.235 118.711
202003 69.916 124.705 93.829
202006 77.391 127.000 101.984
202009 84.624 130.118 108.843
202012 80.094 130.889 102.410
202103 82.101 131.771 104.274
202106 70.206 134.084 87.628
202109 79.102 135.847 97.450
202112 80.253 138.161 97.212
202203 92.863 138.822 111.951
202206 92.922 142.347 109.248
202209 94.481 144.661 109.304
202212 99.907 145.763 114.708
202303 113.867 146.865 129.755
202306 118.164 150.280 131.592
202309 124.438 151.492 137.470
202312 122.316 152.924 133.860
202403 153.298 153.035 167.645
202406 155.138 155.789 166.658
202409 163.180 157.882 172.973
202412 176.116 158.323 186.166
202503 192.192 157.552 204.154
202506 210.507 159.755 220.524
202509 223.654 162.289 230.638
202512 244.706 163.281 250.815
202603 231.416 164.272 235.762
202606 273.083 167.357 273.083

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹524.50 mean?
AstraZeneca Pharma India (BOM:506820) has a Cyclically Adjusted Revenue per Share of ₹524.50 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AstraZeneca Pharma India and its competitors.
Is AstraZeneca Pharma India's Cyclically Adjusted Revenue per Share too high?
AstraZeneca Pharma India's current Cyclically Adjusted Revenue per Share is ₹524.50. Overall, AstraZeneca Pharma India has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Cyclically Adjusted Revenue per Share compare to ZTS?
AstraZeneca Pharma India's Cyclically Adjusted Revenue per Share of ₹524.50 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AstraZeneca Pharma India and its competitors. AstraZeneca Pharma India's current Cyclically Adjusted Revenue per Share is ₹524.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (BOM:506820) is currently considered Possible Value Trap. The stock's GF Value™ is ₹11,404.90, compared to a current price of ₹7,410.50 — trading 35% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹524.50. AstraZeneca Pharma India's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For AstraZeneca Pharma India (BOM:506820), the current Cyclically Adjusted Revenue per Share is ₹524.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca Pharma India (BOM:506820) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued. The current stock price of ₹7,410.50 is trading 35% below its estimated GF Value™ of ₹11,404.90. GuruFocus considers AstraZeneca Pharma India to be Possible Value Trap.

Key valuation signals for BOM:506820:

  • Cyclically Adjusted Revenue per Share: ₹524.50
  • GF Value™: ₹11,404.90 vs. price of ₹7,410.50 (35% below fair value)
  • GF Score™: 85/100 with 6 warning signs

No single metric tells the full story. See the BOM:506820 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Pharma India Business Description

Other Exchanges ASTRAZEN:India
Address Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
85GF Score

Get the complete analysis for BOM:506820

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹7,410.50
Price
₹11,404.90
GF Value